ISDA

Deposition Date 2019-02-25

Release Date 2020-01-22

Last Version Date 2024-03-27

Entry Detail

PDB ID:

6JJB

Keywords:

SIGNALING PROTEIN/INHIBITOR

Title:

BRD4 in complex with ZZM1

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli BL21(DE3)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

1.51 Å

R-Value Free:

0.22

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Bromodomain-containing protein 4
Gene (Uniprot):BRD4
Chain IDs:A
Chain Length:125
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:O60885 Pfam ID:PF00439

Ligand Molecules

BT0

Primary Citation

Discovery of Benzo[cd]indol-2(1H)-ones and Pyrrolo[4,3,2-de]quinolin-2(1H)-ones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain with Potential High Efficiency against Acute Gouty Arthritis.

Jiang, F, Hu, Q, Zhang, Z, Li, H, Li, H, Zhang, D, Li, H, Ma, Y, Xu, J, Chen, H, Cui, Y, Zhi, Y, Zhang, Y, Xu, J, Zhu, J, Lu, T, Chen, Y.Show

J.Med.Chem. 62 11080 11107 (2019)

PMID: 31789032 DOI: 10.1021/acs.jmedchem.9b01010

Abstact

The bromodomain and extra-terminal domain (BET) family of proteins are readers which specifically recognize histone-acetylated lysine residues. Each BET bromodomain protein contains two highly homologous domains: the first bromodomain (BD1) and the second bromodomain (BD2). Pan-BET bromodomain inhibition is a potential therapy for various cancers and immune-inflammatory diseases, but only few reported inhibitors show selectivity within the BET family. Herein, we identified a series of benzo[cd]indol-2(1H)-ones and pyrrolo[4,3,2-de]quinolin-2(1H)-ones with good selectivity for BET BD1. Through structure-based optimization, highly active and selective compounds are ultimately obtained. The representative compounds are the first reported inhibitors with selectivity more than 100-fold for BRD4(1) over BRD4(2). Among them, we further show that 68 (LT052) mediates BRD4/NF-κB/NLRP3 signaling inflammatory pathways with comparable protein expression and significantly improves symptoms of gout arthritis in a rat model. Therefore, selective pharmacological modulation of individual bromodomains could represent a strategy for the treatment of acute gouty arthritis.

Legend

Protein

Chemical

Disease

Primary Citation of related structures